Search results
Showing 766 to 780 of 2185 results for guidelines
This guide describes the process NICE uses to develop NICE quality standards
In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.
This indicator covers patient experiences of dental services. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Awaiting development Reference number: GID-QS10035 Expected publication date: TBC
We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See NICE review 1 on DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)
Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)
Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults
In development Reference number: GID-TA11477 Expected publication date: 12 August 2026
Myocardial infarction: medication for MI in preceding 12 months (IND125)
This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79
This indicator covers the percentage of patients with diabetes who have had the following care processes performed in the preceding 12 months: BMI measurement, BP measurement, HbA1c measurement, cholesterol measurement, record of smoking status, foot examination, albumin:creatinine ratio, eGFR creatinine measurement. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM74
This indicator covers under 75 mortality from liver disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Sole supplied titles are distinct journal and book collections that can be purchased from Lot 1 of our purchasing framework.
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Etanercept and efalizumab for treating moderate to severe plaque psoriasis (TA103)
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.
This indicator covers under 75 mortality from cardiovascular disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes